Scholarlink

<p>Peripherally inserted central catheters (PICCs) are widely used in hematology for chemotherapy, transfusions, and supportive care, but concerns about complications such as thrombosis and central line–associated bloodstream infections (CLABSIs) persist. Indian data are limited. We retrospectively analyzed 199 PICC insertions in 177 hematology patients at a tertiary center in Chennai (July 2020–December 2024), using BD Power PICC 200 double-lumen catheters. Outcomes included infectious, mechanical, and thrombotic events. CLABSIs were defined by Public Health England criteria. Incidence rates were calculated per 1,000 catheter-days and compared across diagnoses with Poisson models. Over 10,854 catheter-days, the overall complication rate was 0.55/1,000 catheter-days. Infections accounted for most events (0.46/1,000), with five CLABSIs (80% gram-negative). Mechanical complications were rare (0.09/1,000); no thromboses occurred. CLABSI rates were higher in leukemia (0.74) and marrow failure syndromes (0.97) than lymphoma (0.00/1,000). CLABSI incidence was significantly higher in leukemia versus lymphoma (<i>p</i> = 0.0227). PICCs provided reliable central venous access with low complication and CLABSI rates, favorable compared with international benchmarks. However, higher CLABSI risk in leukemia and marrow failure highlights the need for vigilant infection surveillance in these subgroups. PICCs remain safe and effective but warrant tailored preventive strategies in high-risk hematology populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety of Peripherally Inserted Central Catheters in Hematology: A Single-Centre Analysis

  • 期刊论文

  • 发表日期：

    2026年2月16日

查看全文
  • Aditya K. Chezhian,
  • Kishore Kumar,
  • Vikas Hampapura Prasadaswamy,
  • Karthikeyan Damodharan,
  • Chezhian Subash

摘要

Peripherally inserted central catheters (PICCs) are widely used in hematology for chemotherapy, transfusions, and supportive care, but concerns about complications such as thrombosis and central line–associated bloodstream infections (CLABSIs) persist. Indian data are limited. We retrospectively analyzed 199 PICC insertions in 177 hematology patients at a tertiary center in Chennai (July 2020–December 2024), using BD Power PICC 200 double-lumen catheters. Outcomes included infectious, mechanical, and thrombotic events. CLABSIs were defined by Public Health England criteria. Incidence rates were calculated per 1,000 catheter-days and compared across diagnoses with Poisson models. Over 10,854 catheter-days, the overall complication rate was 0.55/1,000 catheter-days. Infections accounted for most events (0.46/1,000), with five CLABSIs (80% gram-negative). Mechanical complications were rare (0.09/1,000); no thromboses occurred. CLABSI rates were higher in leukemia (0.74) and marrow failure syndromes (0.97) than lymphoma (0.00/1,000). CLABSI incidence was significantly higher in leukemia versus lymphoma (p = 0.0227). PICCs provided reliable central venous access with low complication and CLABSI rates, favorable compared with international benchmarks. However, higher CLABSI risk in leukemia and marrow failure highlights the need for vigilant infection surveillance in these subgroups. PICCs remain safe and effective but warrant tailored preventive strategies in high-risk hematology populations.